MedTrace Logo

Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

NCT04729972 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-03-26

Study results available
· View outcomes & findings →

Summary

This is a multi-center, open-label, 6-month study to evaluate the safety of bilateral CNTF implants in participants with Macular Telangiectasia Type 2.

Conditions

  • Macular Telangiectasia Type 2

Interventions

COMBINATION_PRODUCT

NT-501 CNTF implant

Single implantation of CNTF-secreting NT-501 device into fellow (untreated) eye

Sponsors & Collaborators

  • The Lowy Medical Research Institute Limited

    collaborator OTHER

  • Neurotech Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Thomas Aaberg, Jr, MD · Neurotech Pharmaceuticals, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-21
Primary Completion
2022-12-08
Completion
2022-12-08
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04729972 on ClinicalTrials.gov